Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Core Insights - Protara Therapeutics reported significant clinical and regulatory advancements for its lead candidate TARA-002, particularly in non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs) [2][3] - The company is on track to complete enrollment for the BCG-Unresponsive cohort of the ADVANCED-2 trial and initiate the ADVANCED-3 trial for BCG-Naïve patients in the second half of 2026 [1][2] - Financially, Protara completed an oversubscribed public offering raising $86 million, with cash reserves expected to support operations into 2028 [1][9] TARA-002 in NMIBC - TARA-002 demonstrated a complete response (CR) rate of 68% at six months in BCG-Unresponsive patients, with a CR rate of 72.4% in BCG-Naïve patients [1][3] - The Kaplan-Meier estimated probability of maintaining a CR for six months was 71.1% for BCG-Unresponsive patients and 73.1% for BCG-Naïve patients [3][4] - The ADVANCED-2 trial is designed to be registrational based on FDA guidance for BCG-Unresponsive NMIBC [10] TARA-002 in LMs - TARA-002 received Breakthrough Therapy and Fast Track designations from the FDA for the treatment of lymphatic malformations, with a regulatory update expected in the first half of 2026 [1][2][8] - The company is working to expedite the treatment's availability to patients [2] IV Choline Chloride for Patients on Parenteral Support - The THRIVE-3 trial for IV Choline Chloride is ongoing, with interim results anticipated in the second half of 2026 [1][5] - This investigational therapy aims to address choline deficiency in patients dependent on long-term parenteral support [15] Financial Performance - For Q4 2025, Protara reported a net loss of $17.3 million, or $0.37 per share, compared to a net loss of $12.8 million, or $0.48 per share, in Q4 2024 [9][22] - Research and development expenses increased to $13.1 million in Q4 2025 from $9.5 million in the prior year, reflecting the advancement of clinical trials [9][22] - As of December 31, 2025, the company had approximately $198 million in cash and cash equivalents, sufficient to fund operations into 2028 [1][9]